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Summary
Background: Drug-eluting stents represent an additional option to treat coronary artery disease. This technology 
represents a major breakthrough that may require additional funding in the short-term to enable its inclusion in 
procedures of the Unified Health System.
Objective: To estimate the impact on the Unified Health System budget in the first year of use of drug-eluting stents.
Methods: A Budget Impact Model was designed to predict the economic impact of the inclusion of drug-eluting stents in 
the Unified Health System budget. Data about costs and local procedures were collected in multiple sources, specifically 
procedure volume data, hospital costs, cost of stents, drug costs and number of stents used in single and multi-vessel 
procedures.
Results: The results in the first year indicate that the impact on the Unified Health System is of 12.8% in the best scenario 
and 24.4% in the worst scenario, representing an increase by R$ 24 to 44 million in the total projected budget.
Conclusion: Drug-eluting stents have an additional cost compared with standard stents in the first year of use in the 
Unified Health System.
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Introduction
In 2003, the Brazilian Unified Health System (SUS) 
financed 30,666 coronary angioplasties with stent placement 
and 19,909 myocardial revascularization surgeries with a total 
cost of approximately R$ 281 million.
The introduction of standard stents in the SUS, in 1999, 
represented a significant change in the interventional 
treatment of patients with ischemic cardiomyopathy. Until 
1999, myocardial revascularization surgery represented 
the main type of interventional treatment. In the three 
subsequent years, the number of coronary angioplasty 
procedures increased by over 100%, with a significant 
decrease in the number of myocardial revascularization 
surgeries during this period. The benefits of treatment 
with standard stents were important although there were 
limitations in some subgroups, especially among patients with 
diabetes, who presented long lesions (>20 mm) and small 
caliber vessels (<3 mm), in which restenosis is significant in 
the first six months after the procedure. 
The development of drug-eluting stents, still not available in 
the SUS, led to significantly lower rates of intra-stent restenosis 
in these subgroups of patients, but with an increase in initial 
cost of treatment. The dilemma that SUS faces is to match the 
budget restriction with the need to evaluate and integrate new 
cardiovascular technologies.
Health economic analyses (e.g. cost-effectiveness) are 
efficient resource allocation tools for policy makers and 
financiers of the Unified Health System; however, they are not 
able to answer the specific financing questions for the object 
of analysis. Therefore, in addition to maximizing efficiency in 
resource allocation, financiers shall analyze if the introduction 
of new technology is compatible with their budget. There are 
specific economic models for budget impact analysis, in which 
the financier estimates the amount of resources needed to 
absorb a new technology based on the additional number of 
patients benefited and the prevalence of the disease.
The objective of this analysis is to provide health 
policymakers and managers with tools for decision making 
on the introduction of drug-eluting stents as a procedure to 
be reimbursed by the SUS.
Methods
The model of decision analysis of the budget impact 
was developed with data obtained from a critical analysis 
of multicenter randomized clinical trials2,3, meta-analysis4, 
systematic review5, data on cardiovascular procedures 
performed by the SUS, data on expenses available at 
DATASUS, database of the Central Nacional de Dados 
(CENIC) [National Data Center] of the Brazilian Society of 
Hemodynamics and Interventional Cardiology (2003 report). 
A panel with experts and members of the Brazilian Society of 
Hemodynamics and Interventional Cardiology (SBHCI) was 
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held to define the reality of cardiology practice in Brazil. 
The assumptions of the budget impact model were: 
conversion rate of conventional to drug-eluting stents, 
number of stents/patients/procedures; percentage of 
reinterventions due to restenosis in standard stents; percentage 
of reinterventions due to restenosis in drug-eluting stents; 
prices of stents; values of AIH (Hospitalization Authorization) 
paid by the SUS to hospitals for procedures including 
angioplasty and myocardial revascularization surgery, price 
of post-procedure clopidogrel. 
The number of myocardial revascularization surgery and 
coronary angioplasty procedures with placement of standard 
stents performed in 2003, by the SUS, was used to estimate 
the increase in budget in face of the hypothetical migration 
to the use of drug-eluting stents. 
Three possible scenarios were created to estimate the 
impact on SUS budget after the introduction of drug-eluting 
stents. These different scenarios are the result of sensitivity 
analyses, where some concepts were modified within the 
variation found in the literature. Scenario 1 adopted a more 
conservative prospect; scenario 2 pictured an intermediate 
condition and scenario 3 presented the most expressive 
prospect for the introduction of drug-eluting stents. Table 1 
summarizes the assumptions used in the model.
The variation in conversion of standard stent to drug-eluting 
stent was 30%, 40% and 50%, according to the variations found 
in the guidelines of the National Institute for Clinical Excellence 
(NICE)6 and the Agence D’Évaluation des Technologies et des 
Modes D’Intervention en Santé (AETMIS)7. 
The estimate of the number of stents per patient in each 
procedure varied between 1.3 and 1.7. This estimate was 
obtained from the Final Report and Recommendations of the 
American Task Force about Drug-Eluting Stents8, the NICE 
guidelines and validation by a panel of specialists of SBHCI. 
Reinterventions due to restenosis in standard stents varied 
between 20% and 15% and in drug-eluting stents it was 4%, 
according to data of a meta-analysis using a hierarchical 
Bayesian model to compare conventional and drug-eluting 
stents9. These reinterventions were treated in the model - 90% 
of them being by coronary angioplasty and 10% by surgical 
myocardial revascularization. This practice standard was 
suggested by the panel of specialists of the SBHCI.
The price of standard stents used in the analysis was the 
value paid by the SUS to accredited hospitals, that is, R$ 
2,580.00. The price of drug-eluting stents was the amount 
reimbursed by the Medicare to the healthcare providers 
in the USA, at R$5,166.00, which characterized as the 
lowest value in the health systems surveyed (Canada, UK, 
France, Australia). The exchange rate was US$ 1 = R$ 2.87 
on June 30, 2003. 
The values used for coronary angioplasty and surgical 
myocardial revascularization were those reimbursed by 
the SUS to accredited health services - R$ 4,989.95 and 
R$ 6,484.84, respectively.
The economic impact of the SBHCI guideline for the 
use of clopidogrel for six months after placement of a drug-
eluting stent and for one month after that of a standard stent 
was incorporated into the model. The price used for this 
medication was that listed in the Brasíndice minus 30%, 
which accounts for the retail marketing margin, with a final 
price of R$123.00.
Results
The best scenario, i.e., the one with lower use of drug-
eluting stents, forecasts a 30% migration from standard stent to 
drug-eluting stent. This scenario would represent an increase 
in the SUS budget by approximately 12.8% in the first year 
of the procedure. The additional cost of the drug, which is 
necessary to avoid intra-stent thrombosis in the first six months, 
would represent one-third 1/3 of total amount. The results of 
scenario 1 are shown in Table 2. 
The intermediate scenario with 40% inclusion of the drug-
eluting stent represents an increase in the SUS budget by 
approximately 20.1% in the first year of the procedure. The 
increase by 10% in the number of patients who are eligible to 
receive drug-eluting stents caused a raise by approximately 35% 
in budget. The results of scenario 2 are shown in Table 3. 
The most dramatic scenario with 50% inclusion of drug-
eluting stents would represent an increase by approximately 
24.4% in the SUS budget in the first year of the procedure. 
In this change of scenario 2 to 3, the 10% increase in the 
number of patients who are illegible to receive drug-eluting 
stents caused an increase by only 18% in the budget. The 
results of scenario 3 are shown in Table 4. 
Table 1 - Comparison of assumptions used in three hypothetical scenarios 
Assumptions Scenario 1 Scenario 2 Scenario 3
Patients treated (CA) com DES 9,199 12,266 15,333
Conversion from standard stent to drug-eluting stent 30% 40% 50%
Stents per patient per  procedure 1.3 1.5 1.7
Percentage of reinterventions due to restenosis in  standard stent 20% 17% 15%
Percentage of reinterventions due to restenosis in drug-eluting stent 4% 4% 4%
Price of drug-eluting stent (R$) 5,166.00 5,166.00 5,166.00
Price of standard stent (R$) 2,580.00 2,580.00 2,580.00
CA - coronary angioplasty; DES - drug-eluting stent.
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Discussion
The analysis of budget impact aims to help decision makers 
at the SUS in their task of critically evaluating the inclusion of 
drug-eluting stents in treatment of patients who are eligible 
to receive this device. 
Health economic models use data of clinical outcomes 
obtained from critical literature analysis. Multicenter clinical 
trials comparing drug-eluting stents versus standard stents 
showed greater efficacy of the former in restenosis outcome. 
This data can be extended to the Brazilian scenario because 
the country participated in all steps of development, research 
and clinical trials of drug-eluting stents.
Data related to costs and clinical practice standards reflect 
the local features, so that the economic model be the most 
accurate possible.
There are some uncertainties in the assumptions that 
comprise the economic models in general due to scarcity 
of data and variability of local medical practice. Such 
limitations are minimized with sensitivity analyses. In 
the model of elaborated impact analysis, we determined 
the variation in the percentage of population access to 
drug-eluting stents and the percentage of reinterventions 
avoided in the 12 subsequent months, in order to help 
decision makers choose the possible scenarios. These 
variations explain the possible scenarios with increase by 
12.8% to 24.4% in the budget in the first 12 months after 
the procedure.
Six brands of drug-eluting stents are authorized by the 
ANVISA (National Health Surveillance Agency) to be traded 
in Brazil in 2006, but only two (Cypher® and Taxus®) 
have long-term follow-up studies (more than three years). 
Table 2 - Scenario 1: Estimate of the impact on the SUS budget by introducing  drug-eluting stent, conversion of 30%
Parameters of 2003 model Total cost 
Hypothetical 
scenario with drug-
eluting stent 
Incremental cost 
Patients treated (CA) 30,666 30,666
Total cost of initial procedure (R$) 152,986,729 176,775,343 23,788,614
Total number of reinterventions due to restenosis 
(90% of CA + 10% of MRS) 6,133 4,660 -1,473
Total cost of reinterventions (90% of CA + 10% of 
MRS) (R$) 31,514,741 23,949,785 -7,564,956
Use of clopidogrel after PTCA 1 month 6 months
Total cost of clopidogrel (R$) 5,366,550 13,415,200 8,048,650
Incremental cost in one year (R$) 24,272,308
Impact on budget in one year (%) 189,868,020 214,140,328 12.8%
CA - coronary angioplasty; MRS - myocardial revascularization surgery.
Table 3 - Scenario 2: Estimate of the impact on the SUS budget by introducing drug-eluting stent, conversion of 40%
Parameters of 2003 model    Total cost 
hypothetical scenario 
with drug-eluting 
stent 
Incremental cost 
Patients treated (CA) 30,666 30,666
Total cost do initial procedure (R$) 152,986,729 184,706,605 31,719,876
Total number of reinterventions due to restenosis 
(90% of CA + 10% of MRS) 4,599 3,250 -1,349
Total cost of reinterventions (90% of CA + 10% of 
MRS) (R$) 23,636,429 16,700,125 -6,939,304
Use of clopidogrel after PTCA 1 month 6 months
Total cost of clopidogrel (R$) 5,366,550 16,569,964 11,803,414
Incremental cost in one year (R$) 36,586,986
Impact on budget in one year (%) 181,989,708 217,976,694 20.1%
CA - coronary angioplasty; MRS - myocardial revascularization surgery.
406
Original Article
Araújo et al
Impact analysis of drug-eluting stent in the unified health system budget
Arq Bras Cardiol 2007; 88(4) : 404-408
The definition of long-term performance of other brands 
requires the publication of randomized clinical trials with 
long-term follow-up.
The result of a small long-term follow-up trial (18 months 
to three years after placement of drug-eluting stents), with 
the purpose of analyzing cost-effectiveness of drug-eluting 
stents with rapamycin and paclitaxel versus standard stents 
(Study BASKET-LATE)10 showed that, in up to one year after 
discontinuation of clopidogrel, the group of patients with 
drug-eluting stents presented two to three times more events 
related to late thrombosis than the group of patients who 
received standard stents.
A meta-analysis conducted by Nordmann et al11 compared 
the first generation drug-eluting stents versus standard 
stents in the outcomes of mortality and Q-wave myocardial 
infarction. These authors reported a higher incidence of 
death and Q-wave myocardial infarction in patients who 
received the first generation drug-eluting stents versus 
standard stents. 
The study BASKET-LATE and the meta-analysis conducted 
by Nordmann et al demonstrated the need to re-evaluate 
the onset time and maintenance time of clopidogrel 
therapy after placement of drug-eluting stents to avoid 
late thrombosis episodes. The study CREDO12 estimated 
the ideal time to start administration of the loading dose 
of 300 mg clopidogrel in patients who underwent coronary 
angioplasty in order to reduce the primary outcomes: 
death, myocardial infarction and urgent revascularization 
of target lesion. There was a reduction by 58.8% in primary 
outcomes in patients who were pre-treated with clopidogrel 
for ≥15 hours before the procedure when compared with 
placebo.
The definition of ideal time of clopidogrel use after 
placement of drug-eluting stents is fundamental for the real 
estimate of the impact on the SUS budget, thus inferring that 
the medication shall be available to patients throughout the 
utilization period and with patient compliance to treatment. 
Our analysis evaluated a time period of six months as per 
the guideline of the SBHCI at that time. However, in view 
of the last publications mentioned above on late thrombosis 
after drug-eluting stent placement, the guidelines have 
been under re-evaluation to standardize a longer use of 
clopidogrel.
Another possible effect of the inclusion of drug-
eluting stents in the SUS is the migration of myocardial 
revascularization surgery to this procedure. Myocardial 
revascularization surgery in Brazil presents mortality rates 
that are much higher than in other countries, in addition 
to a higher financial cost to the SUS. A study conducted by 
Godoy et al, in Brazil, found an overall mortality rate of 7.8% 
for myocardial revascularization surgery adjusted to age, sex 
and diagnostic groups, between 1999-200313. Migration of 
myocardial revascularization surgery to placement of drug-
eluting stents was analyzed in a study conducted at the Mayo 
Clinic14. The authors concluded that up to 46% of patients 
who underwent myocardial revascularization surgery would 
be eligible for drug-eluting stents. 
It is probable that in the subgroup of diabetic patients 
in whom the restenosis rate is higher than in non-diabetic 
individuals15, the cost-effectiveness ratio is more attractive 
for the inclusion of drug-eluting stents, with lower impact on 
the financier’s budget. 
Conclusion
With the fast technological development, especially 
in the cardiovascular field, the evaluation of inclusion 
of new technologies is essential not only to identify the 
interventions relevant to the health system, but also to choose 
the alternatives that actually aggregate value to the health 
system (Table 5).
The discussion about the inclusion of new technologies in 
the SUS is an opportunity for the Brazilian Cardiology Society 
to foster the development of methods that help cardiovascular 
Table 4 - Scenario 3: Estimate of the impact on the SUS budget by introducing drug-eluting stent, conversion of 50%
Parameters of 2003 model Total cost 
Hypothetical scenario 
with drug-eluting 
stent 
Incremental cost 
Patients treated (CA) 30,666 30,666
Total cost of initial procedure (R$) 152,986,729 192,637,867 39,651,138
number of reinterventions due to restenosis (90% 
of CA + 10% of MRS) 4,599 2,913 -1,686
Total cost of reinterventions (90% of CA + 10% of 
MRS) (R$) 23,636,429 14,965,746 -8,670,683
Use of clopidogrel after PTCA 1 month 6 months
Total cost of clopidogrel (R$) 5,366,550 18,844,257 13,477,707
Incremental cost in one year (R$) 44,458,162
Impact on budget in one year (%) 181,989,708 226,447,870 24.4%
CA - coronary angioplasty; MRS - myocardial revascularization surgery.
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health policy makers in the process of choosing between the 
alternatives available, by measuring the benefits for each cost 
Table 5 - Comparison of results of three hypothetical scenarios of drug-eluting stent introduction.
Parameters of 2003 model Scenario 1 Scenario 2 Scenario 3
Patients treated (CA) = DES + CS 30,666 30,666 30,666
Total cost of initial procedure (R$) 176,775,343 184,706,605 192,637,867
Total number of reinterventions due to restenosis 
(90% of CA + 10% of MRS) 4,660 3,250 2,913
Total cost of reinterventions (90% of CA + 10% of 
MRS) (R$) 23,949,785 16,700,125 14,965,746
Use of clopidogrel after PTCA 6 months 6 months 6 months
Total cost of clopidogrel (R$) 13,415,200 16,569,964 18,844,257
Incremental cost in one year (R$) 24,272,308 36,586,986 44,458,162
Impact on budget in one year (%) 12.8% 20.1% 24.4%
CA - coronary angioplasty; MRS - myocardial revascularization surgery; DES - drug-eluting stent; CS - standard stent. 
unit and the estimated return to society with the inclusion of 
new diagnostic and therapeutic models.
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